EOD v2.0 Known Issues:
- Cervix [8th: 2018-2020], EOD Primary Tumor, Code 550: the text was accidentally overwritten. It will be replaced next version. There were no changes from the v1.7 text for this code (https://staging.seer.cancer.gov/eod_public/input/1.7/cervix/eod_primary_tumor/)
- January, 2021: In Melanoma Skin, the LDH Level [#3869] was adjusted to remove pretx. This was not done for the Plasma Cell Myeloma field until January, but a corrected version was posted. Please verify you are using latest version of the library/api.
- April, 2021: In Testis, S Category Pathological [#3924] had a value of 5 added. This value was not added to the calculation table for Derived EOD Stage Group [#818]. If you are required to have a valid value for Derive EOD Stage Group, and S Category Pathological is set to 5, please change S Category Pathological to 0. The calculation table will be corrected in v2.1.
EOD v2.0 Review and Conversion:
- If Schema ID [#3800] = 00060 (Cervical Lymph Nodes, Unknown Primary of Head and Neck)
- If EOD Regional Nodes [#774] = 000, convert Schema Discriminator 1 [#3926] = 1 and manually review. (Changes the schema)
(The value of 000 was not reused, so this conversion can always be applied.)
- If EOD Regional Nodes [#774] = 000, convert Schema Discriminator 1 [#3926] = 1 and manually review. (Changes the schema)
- If Schema ID [#3800] = 00112 (Hypopharynx), 00118 (Pharynx Other), 00119 (Middle Ear), 00121 (Maxillary Sinus), 00122 (Nasal Cavity and Ethmoid Sinus), 00128 (Sinus Other)
- If EOD Primary Tumor [#772] = 800, convert Primary Site [#400] to C760 and manually review. (Changes the schema)
(The value of 800 was not reused, so this conversion can always be applied.)
- If EOD Primary Tumor [#772] = 800, convert Primary Site [#400] to C760 and manually review. (Changes the schema)
- If Schema ID [#3800] = 00290 (NET Stomach) and EOD Mets [#776] = 20 or 30:
- These values flipped: Recode EOD Mets = 20 to be EOD Mets = 30; Recode EOD Mets = 30 to be EOD Mets = 20
(Since the values are still both used, you may wish to consider an edit requiring a manual review of cases with these values if the Schema ID Version Original < 2.0)
- These values flipped: Recode EOD Mets = 20 to be EOD Mets = 30; Recode EOD Mets = 30 to be EOD Mets = 20
- If Schema ID [#3800] = 00360 (Lung)
- If Visceral and Parietal Pleural Invasion [#3937] = 1 or 2, convert Visceral and Parietal Pleural Invasion = 4
- If Visceral and Parietal Pleural Invasion = 3, convert Visceral and Parietal Pleural Invasion = 5
(The values of 1 - 3 were not reused, so this conversion can always be applied. No review necessary)
- If Schema ID [#3800] = 00382 (Bone Spine)
- If EOD Primary Tumor [#772] = 600, convert to EOD Primary Tumor = 750.
(The value of 600 was not reused, so this conversion can always be applied. No review is necessary)
- If EOD Primary Tumor [#772] = 600, convert to EOD Primary Tumor = 750.
- If Schema ID [#3800] = 00421 (Soft Tissue Abdomen and Thoracic) and Primary Site [#400] = C473, C475, C493-C495 and Date of Diagnosis [#390] is 2018-2020,
- Set Schema Discriminator 2 [#3927] = 8
(8 indicates a 2018-2020 diagnosis, so this can always be applied. No review is necessary)
- Set Schema Discriminator 2 [#3927] = 8
- If Schema ID [#3800] = 00500 (Vulva), 00510 (Vagina), 00520 (Cervix), 00530 (Corpus Carcinoma and Carcinosarcoma), 00541 (Corpus Sarcoma), 00542 (Corpus Adenosarcoma), 00551 (Ovary), 00552 (Primary Peritoneal Carcinoma), 00553 (Fallopian Tube) or 00560 (Placenta), for FIGO Stage [#3836]
- FIGO stage is being converted from a 2 digit code to the actual stage values
01 -> 102 -> 1A03 -> 1A104 -> 1A205 -> 1B06 -> 1B107 -> 1B208 -> 1C09 -> 1C110 -> 1C211 -> 1C320 -> 221 -> 2A22 -> 2A123 -> 2A224 -> 2B30 -> 331 -> 3A32 -> 3A133 -> 3A1134 -> 3A1235 -> 3A236 -> 3B37 -> 3C38 -> 3C139 -> 3C240 -> 441 -> 4A42 -> 4B(These values are not reused, so this conversion can always be applied. No review is necessary.)
- FIGO stage is being converted from a 2 digit code to the actual stage values
- If Schema ID [#3800] = 00530 (Corpus Carcinoma and Carcinosarcoma)
- If Histology ICDO3 [#522] = 8380 and Behavior ICDO3 [#5423] = 2, manually review and set EOD Primary Tumor [#772] = 050, 070 or 080 as appropriate.
(This should always be done; AJCC ID will change to 53)
- If Histology ICDO3 [#522] = 8380 and Behavior ICDO3 [#5423] = 2, manually review and set EOD Primary Tumor [#772] = 050, 070 or 080 as appropriate.
- If Schema ID [#3800] = 00551 (Ovary)
- If Histology ICDO3 [#522] = 8441 and Behavior ICDO3 [#5423] = 2, Set EOD Primary Tumor [#772] = 050.
(This could always be applied; AJCC ID will change to 55. No review is necessary)
- If Histology ICDO3 [#522] = 8441 and Behavior ICDO3 [#5423] = 2, Set EOD Primary Tumor [#772] = 050.
- If Schema ID [#3800] = 00553 (Fallopian Tube)
- If Histology ICDO3 [#522] = 8441 and Behavior ICDO3 [#5423] = 2, manually review and set EOD Primary Tumor [#772] = 050, 070 or 080 as appropriate.
(This should always be done; AJCC ID will change to 55)
- If EOD Primary Tumor [#772] = 200 EITHER correct the EOD Primary Tumor or change Primary Site [#400] to C569 and manually review the case (Schema would be Ovary)
(The value of 200 was not reused, so this review can always be required.)
- If Histology ICDO3 [#522] = 8441 and Behavior ICDO3 [#5423] = 2, manually review and set EOD Primary Tumor [#772] = 050, 070 or 080 as appropriate.
- If Schema ID [#3800] = 00551 (Ovary), 00552 (Primary Peritoneal Carcinoma) or 00553 (Fallopian Tube)
- If Residual Tumor Volume Post Cytoreduction [#3921] = 10, 20, convert Residual Tumor Volume Post Cytoreduction = 50
- If Residual Tumor Volume Post Cytoreduction = 30, 40, convert Residual Tumor Volume Post Cytoreduction = 60
- If Residual Tumor Volume Post Cytoreduction = 90, 91, convert Residual Tumor Volume Post Cytoreduction = 70
- If Residual Tumor Volume Post Cytoreduction = 92, 93, convert Residual Tumor Volume Post Cytoreduction = 80
(The values of 10-40, 90-93 were not reused, so this conversion can always be applied. No review necessary)
- If Schema ID [#3800] = 00671 (Melanoma Iris)
- If EOD Regional Nodes [#774] = 400, convert EOD Regional Nodes = 300 and manually review. (Discrete tumor nodules do not apply to Iris, so original coding was questionable)
(The value of 400 was not reused, so this conversion can always be applied.)
- If EOD Regional Nodes [#774] = 500, convert EOD Regional Nodes = 300
(The value of 500 was not reused, so this conversion can always be applied. No review is necessary)
- If EOD Regional Nodes [#774] = 400, convert EOD Regional Nodes = 300 and manually review. (Discrete tumor nodules do not apply to Iris, so original coding was questionable)
- If Schema ID [#3800] = 00672 (Melanoma Choroid and Ciliary Body)
- If EOD Regional Nodes [#774] = 500, convert EOD Regional Nodes = 300
(The value of 500 was not reused, so this conversion can always be applied. No review is necessary)
- If EOD Regional Nodes [#774] = 500, convert EOD Regional Nodes = 300
- If Schema ID [#3800] = 00690 (Lacrimal Gland), for each of Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy [#3845]
- If Grade = A, convert Grade = 1
- If Grade = B, convert Grade = 2
- If Grade = C, convert Grade = 3
- If Grade = D, convert Grade = 4
(These values are not reused so this conversion can always be applied. No review is necessary.)
- If Schema ID [#3800] = 00710 (Lymphoma Ocular Adnexa), for each of Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy [#3845]
- If Grade = 4, convert Grade = 3
- If Grade = 5, convert Grade = 4
- If Grade = L, convert Grade = 9
(Codes 5 and L are not reused, so those conversions can always be applied. No review is necessary. However, Code 4 is still used, so you may wish to consider an edit requiring a manual review of cases with these values if the Schema ID Version Original < 2.0)
- If Schema ID [#3800] = 00822 (Plasma Cell Disorders) and EOD Primary Tumor [#772] = '500'
- Histology ICDO3 [#522] = 9731 or 9734, convert Histology ICDO3 [#522] = 9732 and manually review. (Changes the schema)
(The value 500 was not reused so this conversion can always be applied)
- Histology ICDO3 [#522] = 9731 or 9734, convert Histology ICDO3 [#522] = 9732 and manually review. (Changes the schema)
Some derivations were changed, including the determination of AJCC ID [#995] for several Female Genital schemas. If you use the EOD or SS2018 derived fields, we recommend running all cases through the algorithms again.
EOD v2.0 changes:
EOD and SS2018
includes changes to schema definitions, EOD fields and SS2018
- General
Histology: the new histology codes were added to the valid histology list and appropriate schemas. 8157, which was obsolete and not allowed by edits, was removed.8444 was removed (see 8313); 8473 was removed (see 8472); 8965 was removed (see 9013). AJCC ID calculation tables were updated. Schema Notes and SS2018 notes related to histology were updated as necessary (8104, 8273, 8348, 8349, 8563, 8643, 8816-8818, 8828, 8992, 9126, 9138, 9211-9213, 9222, 9563, 9715, 9749, 9819, 9877-9879, 9912, 9969, 9993 added; 8157, 8444, 8473, 8965 removed)Footnotes: the page numbers for all footnotes referencing the AJCC Cancer Staging Manual have had the page numbers removed at the request of the AJCCNotes: the word 'considered' was removed from all EOD fields and SSDIs, 25 occurrences in various schemas. Some wording was slightly modified to adjust.Notes: for fields included in the API that are not strictly staging fields (Primary Site, Histology, Behavior, Year of Diagnosis, Regional Nodes Examined, Regional Nodes Positive, LVI, Tumor Size Clin, Path and Summary, RX Summ Surg/Rad Sequence, RX Summ Systemic/Surg Sequence), a note was added to see the SEER Program Coding Manual for instructions. Many of these fields are primarily used for the API calculations, but in case they are used to populate a selection list in a registry application, the rules for coding the fields are found elsewhere.
- AJCC 9th Edition
NOTE: As new Editions for AJCC chapters are released, an additional version of the affected schema will be created. The schemas will have the year of diagnosis as a discriminator. If the value that is sent in for year of diagnosis is 9999 (unknown), the most recent schema will be returned. If you have cases with year of diagnosis = 9999 currently in your database, please give careful thought to how you will handle them. For example, for unknown date of diagnosis, you may wish to pass in the year the case was collected/created so the coding rules for that year are applied.TNM Edition Number has been added to the AJCC ID calculation table (tag = ajcc_version_number)CERVIX: AJCC released the 9th revision of the Cervix chapter. There are now 2 Cervix schemas:- Cervix [8th: 2018-2020], Schema ID [#3800] = 00520, Edition = 08
- Cervix [9th: 2021+], Schema ID = 09520, Edition = 09
- Ampulla of Vater
EOD Primary Tumor: Code 150 is now contributing L to SS2018 rather than RE; Code 700 had 'Periduodenal or peripancreatic soft tissue with involvement of structures in codes 500 or 600' added
- Appendix
EOD Primary Tumor: Notes 1 to 6 were added to the table; Code 600 had '(ICD-O-3 codes 8480/3, 8481/3, and 8490/3 only)' added after 'Mucinous tumors only' for clarity; Code 750 had "Mucinous tumors only (ICD-O-3 codes 8480/3, 8481/3, and 8490/3 only)" with the sub-bullet "Structures in code 700 with peritoneal involvement confined within right lower quadrant" addedEOD Mets: Note added to describe when code 70 should be used; Code 40 was added for Distant lymph nodes, with or without intraperitoneal metastasis; Code 50 had Distant lymph nodes removed and was streamlined
- Bladder
EOD Primary Tumor: Note 4 was changed to "In case of multifocal noninvasive tumors (code 000) and in situ tumors (code 050), code 050."; Code 000 and 050 were revised to clarify use of 000 for 8130/2 and 8131/2 only; Code 050 had 'papillary and nonpapillary' added to clarify multifocal cancer coding; Code 500 had '(Clinically or grossly apparent extravesical mass)' added; Code 550 had 'Unknown if microscopic or macroscopic added; Code 720 had "Bladder is “fixed” with extension to structures in code 650" addedEOD Mets: Note added to describe when code 70 should be used; Code 10 changes to list specific nodes; Code 50 was added for distant mets with or without distant lymph nodes and Carcinomatosis; Code 70 was changed to only be distant metastasis, NOSSS2018: Code 0 was revised and expanded to better define Papillary and nonpapillary, and 'Multifocal non-invasive tumors' was added
- Bone Appendicular Skeleton, Bone Pelvis, Bone Spine
EOD Mets: Note added to describe when code 70 should be used; Code 30 had 'with or without lung metastasis' added; Code 50 was clarified to be with or without distant lymph nodes or lung metastasis, Other specified distant metastasis was added
- Bone Spine
EOD Primary Tumor: Code 600, which is analogous to a T4, was moved to code 750 **(See ‘EOD v2.0 Review and Conversion’)**; Code 650 is now contributing RE to SS2018 rather than D
- Brain
SS2018: Code 2 changed to start with 'Regional by direct extension only'
- Breast
EOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 6 was added to clarify meaning of internal mammary nodes; Code 000 had 'CLINICAL assessment only' added; Code 070 had 'PATHOLOGICAL assessment only' added
- Buccal Mucosa, Floor of Mouth, Gum, Lip, Mouth Other, Palate Hard, Tongue Anterior
EOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removed
- Cervical Lymph Nodes and Unknown Primary of Head and Neck
Schema Note 4 and SS2018 Note 5 were updated to include C000-C002, C006EOD Regional Nodes: Note 2 was added to clarify that 000 does not apply to this schema and coding issues surrounding that; Note 3 defining Clinical and Pathological assessment was added; Note 5 (supraclavicular) was revised for clarity; Code 000 was removed as positive nodes are required for this schema **(See ‘EOD v2.0 Review and Conversion’)**; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removedDefault for Tumor Size Clinical [#752], Pathological [#754], and Summary [#756] were changed to 000; this is part of the definition of this schema
- Cervix
EOD Primary Tumor: Code 250 had 'FIGO Stage IB1, IB2' addedEOD Mets: Code 10 was clarified to be 'Inguinal (femoral)'SS2018: Codes 1, 2 and 7 restructured; Code 1 had FIGO IB1 and IB2 added; Code 3 had a section for FIGO IIIC added; Code 7 had 'femoral' added after 'Inguinal'
- Colon and Rectum
EOD Primary Tumor: Note 5 has bullets for codes 300 and 400 – under the 2nd sub-bullet of those, ‘Upper two thirds of rectum’ was addedEOD Mets: Note 1 about code 70 was added; Note 2 about coding Peritoneal involvement was added; Code 30 had ‘Single distant lymph node chain with single distant organ (except peritoneum)’ addedSS2018: Note 6 has bullets for codes Localized and Regional – under the 2nd sub-bullet of those, ‘Upper two thirds of rectum’ was added
- Corpus Carcinoma and Carcinosarcoma
AJCC ID for 8380/2 changed to be 53EOD Primary Tumor: Note 2 describing 050, 070 and 080 was added; Code 050, 070 and 080 were added to handle 8380/2 **(See ‘EOD v2.0 Review and Conversion’)**SS2018: Codes 1, 2 and 7 restructured; Code 0 had 'Endometrial intraepithelial carcinoma (EIC)' added; Code 3 had section for FIGO Stage IIIC added; Code 7 have several sites added to Distant site list
- Corpus Sarcoma, Corpus Adenosarcoma
SS2018: Codes 1, 2 and 7 restructured; Code 3 had section for FIGO Stage IIIC added; Code 7 have several sites added to Distant site list
- Cutaneous Carcinoma of Head and Neck
EOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removed
- Cystic Duct
EOD Primary Tumor: Code 600 had 'Extrahepatic bile ducts (including common bile duct) with extension to gallbladder or structures in codes 400-500 OR ONE of the following' added; Code 650 has 'Two or more organs and/or structures listed in code 600' added
- Esophagus and Esophagus Squamous
EOD Primary Tumor: Code 700 had "Code (500) + (600)" added
- Fallopian Tube
AJCC ID for 8441/2 changed to be 55EOD Primary Tumor: Note 2 was added describing codes 050, 070 and 080; Note 3 sub-bullet changed to 'Ascites, NOS should be excluded as a staging element'; Note 4 was added describing how to handle involvement of ovary; Note 5 had bullets added for Adjacent peritoneum, Ligaments and Mesosalpinx; Note 9 about liver and splenic involvement was reworded for clarity; Codes 050 (High grade STIC, one tube), 070 (High grade STIC, both tubes) and 080 (High grade STIC, unknown how many tubes) were added **(See ‘EOD v2.0 Review and Conversion’)**; Code 100 had STIC removed; Code 200 was completely removed **(See ‘EOD v2.0 Review and Conversion’)**; Code 250 had capsule rupture removed; Code 450 was simplified; Code 600 was simplified and is now contributing D to SS2018 rather than RE; Code 650 was re-organized; Code 700 was reorganized and Extensions to liver and splenic capsule was addedSS2018: 'High-grade serous tubal intraepithelial carcinoma (STIC)' was added to Code 0; Codes 1, 2 and 7 restructured; Code 1 had FIGO IC and IC NOS dropped; Code 2 had several sites added to extension list and text for IIIA dropped; Code 3 had section for FIGO IIIA1 added; Code 7 had several sites specified for Distant site list and IIIA and IIIA2 added
- Floor of Mouth
EOD Primary Tumor: Code 600 had "Involvement of deep (extrinsic) muscle of tongue with extension to structures listed in Note 2" added
- Heart, Mediastinum, and Pleura
EOD Primary Tumor: Note 1 added to confirm 000 does not apply to this schema; Note 2 added to define multifocal; Code 500 had ‘Adjacent organs/structures NOS’ removed
- HemeRetic
Schema Notes, EOD Primary Tumor Notes, SS2018 Notes: updated with new histologies and year limitations where appropriateEOD Primary Tumor: Note 3 had '9740: Mast cell sarcoma' removed
- Hypopharynx
EOD Primary Tumor: Code 700 had "Carotid artery (encased) with involvement of the hyoid bone" added; Code 800 was removed **(See ‘EOD v2.0 Review and Conversion’)**EOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removed
- Kidney Parenchyma
EOD Primary Tumor: 'Pelvicalyceal system; Renal pelvis or calyces involved; Separate focus of tumor in renal pelvis/calyx' moved from Code 100 to Code 200SS2018: 'Pelvicalyceal system; Renal pelvis or calyces involved; Separate focus of tumor in renal pelvis/calyx' moved from Code 1 to Code 2
- Kidney Renal Pelvis
EOD Primary Tumor: Note 1 changed to 'In case of multifocal papillary noninvasive tumors (code 000) and nonpapillary in situ tumors (code 050), code 050.'; Codes 000 and 050 were revised to clarify use of 000 and 050; Code 050 had 'papillary and nonpapillary' added to clarify multifocal cancer codingEOD Regional Nodes: Code 200 had 'SINGLE regional lymph node, size UNKNOWN' addedSS2018: Code 0 revised to clarify Papillary and Nonpapillary, and 'Multifocal non-invasive tumors' was added
- Lacrimal Gland
EOD Primary Tumor: Code 700 had Orbital bone and Periosteum removed
- Larynx Glottic
EOD Primary Tumor: Code 250 was reorganized and several sub-bullets were added; Code 400 had '(minor erosion)' added to Thyroid CartilageSS2018: Note 5 added clarifying Code 1; Code 7 had '(encased)' added after Carotid artery
- Larynx Other
EOD Primary Tumor: Code 200 had '(minor erosion)' added to Thyroid CartilageSS2018: Note 5 added clarifying Code 1; Code 7 had '(encased)' added after Carotid artery
- Larynx Subglottic
EOD Primary Tumor: Code 400 had '(minor erosion)' added to Thyroid CartilageSS2018: Note 5 added clarifying Code 1; Inner cortex of thyroid cartilage and paraglottic space moved from Code 1 to Code 2; 'Limited to larynx with vocal code fixation' removed from Code 1; Code 7 had '(encased)' added after Carotid artery, and had 'Thyroid cartilage (outer cortex, NOS)' added
- Larynx Supraglottic
EOD Primary Tumor: Code 600 had "Thyroid cartilage (inner cortex) (inner erosion) with extension to structures in code 500" addedSS2018: Code 7 had '(encased)' added after Carotid artery
- Larynx Glottic, Larynx Other, Larynx Subglottic, Larynx Supraglottic
EOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removed
- Lip
EOD Primary Tumor: Code 700 had "Invasion through cortical bone with extension to structures in code 600" added
- Liver
EOD Primary Tumor: Code 200 is now contributing RE to SS2018 rather than LSS2018: Multiple (satellite) nodules/tumors confined to one lobe moved from Code 1 to Code 2
- Lung
EOD Primary Tumor: Code 500 had diaphragm added; Code 650 had "Code 600 + (100-500); Carina with involvement of any other parts of lung" addedEOD Mets: Codes 20, 30 and 50 had 'with or without metastasis listed in code 10' added
- Lymphoma
Schema Notes, SS2018 Notes: updated with new histologies and year limitations where appropriate
- Lymphoma and Lymphoma CLL/SLL
EOD Primary Tumor: Notes 11 (Bone Marrow) and 12 (Peripheral blood involvement) were flipped; (new) Note 11 modified to revise and clarify how Peripheral blood involvement should be coded - this affects how one codes Mets at DX - Other [#1117] as well; Codes 100-400, 600, and 700 were reorganized and rephrased; Code 750 "Peripheral blood involvement ONLY" was added; Code 800 was reorganized and rephrasedSS2018: Codes 1, 2 and 7 reformatted; Code 2 changed to start with 'Regional by direct extension only'
- Lymphoma Ocular Adnexa
EOD Regional Lymph Nodes: Code 750 was addedTumor Size Clinical, Pathological and Summary: Valid value list changed from just 999 to be the standard valid value list
- Major Salivary Glands
EOD Primary Tumor: Code 500 had "Structures in code 400 with spinal accessory nerve involvement" added; Code 700 had "Internal carotid artery or jugular vein with extension to structures in codes 350-500" addedEOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removed
- Maxillary Sinus, Nasal Cavity and Ethmoid Sinus
EOD Primary Tumor: Code 800 was removed **(See ‘EOD v2.0 Review and Conversion’)**EOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removed
- Melanoma Choroid and Ciliary Body
EOD Primary Tumor: Note 3 added describing how to code Discrete tumor deposits; Code 700 changed to say 'Extraocular extension, NOS, UNKNOWN measurement, WITH or WITHOUT ciliary body involvement' and is now contributing RE to SS2018 rather than DEOD Regional Nodes: Code 300 had ‘with or without discrete tumor nodules in the orbit not contiguous to the eye’ added; Code 500 was removed **(See ‘EOD v2.0 Review and Conversion’)**
- Melanoma Iris
EOD Primary Tumor: Note 1 added to warn of infrequency of Iris tumors; Note 2 added describing how to code discrete tumor deposits; Code 700 s now contributing RE to SS2018 rather than DEOD Regional Nodes: Codes 400 and 500 were removed **(See ‘EOD v2.0 Review and Conversion’)**
- Melanoma Choroid and Ciliary Body, Melanoma Iris
EOD Mets: Note 1 added to define how to code for multiple metastatic sites; Note 2 added to describe when code 70 should be used; Codes 10, 30 and 50 had 'Distant lymph node(s) and/or other distant metastasis' added; Code 70 revised to match style of codes 10, 30 and 50SS2018: 'further contiguous extension' moved from Code 7 to Code 2
- Melanoma Conjunctiva
EOD Primary Tumor: Note 2 was removed (this is a general rule)
- Melanoma Head and Neck
EOD Primary Tumor: Code 700 is now contributing RE to SS2018 rather than D
- Melanoma Skin
AJCC ID for C500 was changed to derive XX rather than 47; this would update automatically when the calculation is run across the databaseEOD Primary Tumor: Note 4 revised to include specific Level in Code descriptionsEOD Regional Nodes: Note 2 added to describe criteria for coding; Codes 100, 400, 600 had 'detected by SLN biopsy' removed (this is an example, not the sole method)
- Merkel Cell Skin
EOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 describing bilateral and contralateral nodes was removed; Note 5 describing contiguous or secondary nodal basins was removed; (new) Note 5 sub-bullet now includes Bilateral or Contralateral lymph nodes, and sub-bullet has been removed; Section for Skin of Trunk (C445) has been removedEOD Mets: Note added to describe when code 70 should be used
- Middle Ear, Pharynx Other, Sinus Other
EOD Primary Tumor: Code 800 was removed **(See ‘EOD v2.0 Review and Conversion’)**
- NET Adrenal Gland
EOD Mets: Note 1 added to clarify that code 50 requires Bone and another mets site while code 30 is for non-bone multiple mets; Note 2 added to define when code 70 should be used; Code 30 had ‘other specified distant metastasis, carcinomatosis, and with or without distant lymph node(s)' added; Code 50 was adjusted to be Bone with at least one of distant lymph nodes, liver, lung or other specified metastasis
- NET Ampulla of Vater, NET Appendix, NET Colon and Rectum, NET Duodenum, NET Jejunum and Ileum, NET Stomach
EOD Mets: Note 1 added to clarify that code 50 requires Liver and another mets site while code 30 is for non-liver multiple mets; Note 2 added to define when code 70 should be used; Code 10 was expanded to 'Liver (including liver parenchymal nodule(s))' to match NET Colon and Rectum; Code 30 for extrahepatic site was standardized for clarity as in NET Ampulla of Vater and in order to add 'Other specified distant metastasis (except liver)' and 'Carcinomatosis'; Code 50 standardized for clarity to Liver WITH other distant metastasis, (10) + (other codes)
- NET Pancreas
EOD Regional Nodes: Code 300 revised to include Site codes, a section for C253-C259 was addedEOD Mets: Note 4 added to clarify that code 60 requires Liver and another mets site while code 30 is for non-liver multiple mets; Note 5 added to define when code 70 should be used; Code 10 was expanded to 'Liver (including liver parenchymal nodule(s))' to match NET Colon and Rectum; Code 50 for extrahepatic site was standardized for clarity as in NET Ampulla of Vater and in order to add 'Other specified distant metastasis (except liver)' and 'Carcinomatosis'; Code 60 standardized for clarity to Liver WITH other distant metastasis, (10) + (other codes); Code 40 had sections for C251-C252 and all sites added; Nodes for C250 were re-organized;
- NET Stomach
EOD Mets: Codes 20 and 30 were flipped so that Code 20 is Distant Lymph Nodes **(See ‘EOD v2.0 Review and Conversion’)**
- Oropharynx HPV-Mediated (p16+)
EOD Primary Tumor: Code 400 had "or other structures in code 200" addedEOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity
- Oropharynx p16-
EOD Primary Tumor: Code 400 had "or other structures in code 200" added; Code 700 had "Prevertebral fascia/muscle with extension to structure in code 550" addedEOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Note 4 (supraclavicular) was revised for clarity; Codes 100, 200-400 had 'CLINICAL OR PATHOLOGICAL' removed
- Ovary
AJCC ID for 8441/2 changed to be 55EOD Primary Tumor: Note 2 added to describe Code 050; Note 3 sub-bullet modified to exclude Ascites NOS; Note 4 added to clarify how to code involvement of fallopian tube; Note 9 was revised to clarify how to handle liver and splenic capsule involvement; Code 050 (Serous EIC) was added **(See ‘EOD v2.0 Review and Conversion’)**; Code 450 was simplified with a reference to Note 5 added; Code 600 is now contributing D to SS2018 rather than RE; Codes 600 and 650 modified to refer to Note 8; Code 700 modified to include liver and splenic capsule involvement
- Ovary, Fallopian Tube, Primary Peritoneal Carcinoma
SS2018: 'High-grade serous tubal intraepithelial carcinoma (STIC)' was added to code 0; Codes 1, 2 and 7 restructured; Code 2 had Corpus uteri and Pelvic wall sites added to extension list and text for IIIA dropped; Code 3 had section for FIGO IIIA1 added; Code 7 had several sites specified for Distant site list and FIGO IIIA and IIIA2 added
- Pancreas
EOD Regional Nodes: Code 700 text expanded to clarify which site codes can use this codeEOD Mets: Code 10 had note clarifying how Celiac should be coded for C251-C259; Code 20 had sections for C251-C252 and all sites added; Nodes for C250 were re-organized
- Pancreas, NET Pancreas
EOD Regional Nodes: Code 300 expanded to include Site code, a section for C253-C259 was added, for Pancreas Head, Pyloric entries were combined;SS2018: Code 3 had a section for C253-C259 nodes added; Code 7 for Distant lymph nodes of C251-C252 had Portal vein and Lateral wall (right) added, nodes for C250 restructured
- Penis
EOD Primary Tumor: Code 070 had '(ICD-O-3 code 9051/3 only)' addedEOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added
- Placenta
EOD Mets: Note 2 added to define when code 70 should be used; Code 30 had 'with or without lung metastasis' addedSS2018: Codes 1, 2 and 7 restructured; Code 7 have FIGO III and IV added specifically
- Plasma Cell Disorders
EOD Primary Tumor: Note 4 added clarifying how to code multiple lesions; code 500 was removed **(See ‘EOD v2.0 Review and Conversion’)**EOD Regional Nodes: Code 800 is now contributing RN to SS2018 rather than NA
- Plasma Cell Myeloma, Plasma Cell Disorders
SS2018: Code 7 was restructured
- Primary Cutaneous Lymphoma
EOD Primary Tumor: Code 700 had 'UNKNOWN if contiguous or discontiguous' addedEOD Regional Nodes: Code 500 had 'Cenowal' corrected as 'Central'SS2018: Code 3 had 'Cenowal' corrected as 'Central'
- Primary Peritoneal Carcinoma
EOD Primary Tumor: Note 4 organ list modified and some entries were added; Note 7 was revised to clarify how to handle liver and splenic capsule involvement; Code 450 was simplified with a reference to Note 4 added; Code 600 is now contributing D to SS2018 rather than RE; Codes 600 and 650 modified to refer to Note 6; Code 700 modified to include liver and splenic capsule involvement
- Prostate
Prostate Pathologic Extension [#3919] has been renamed to be 'EOD Prostate Pathologic Extension' and data item tag changed to eod_prostate_path_extensionEOD Primary Tumor: Note 3 sub-bullet 3 revised to disallow imaging findingsEOD Mets: Note added to define when code 70 should be used; Code 50 wording was re-organized and 'specified' distant mets was clarifiedSS2018: Note 4 was revised to include 'with no other evidence of lymph node involvement or distant metastatic involvement'; Note 5 was revised to exclude imaging
- Retinoblastoma
EOD Primary Tumor: Note 2 defining Clinical and Pathological assessment was added; Codes 300 and 550 had 'CLINICAL OR PATHOLOGICAL' removed
- Soft Tissue Abdomen and Thoracic
EOD Primary Tumor: Note 2 added to define multifocal; Code 500 had ‘Adjacent organ(s)/Structure(s), NOS removed
- Testis
EOD Primary Tumor: Note 1 about Pathological assessment was revised for clarity; Note 2 about definition of Pure seminomas was added; Code 100 and 150 had '(ICD-O-3 code 9061/3 only)' addedEOD Regional Nodes: Note 2 defining Clinical and Pathological assessment was added; Codes 000 and 600 had ‘CLINICAL OR PATHOLOGICAL’ removedEOD Mets: Note 2 added to define when code 70 should be used; Code 60 wording was re-organized
- Thymus
EOD Primary Tumor: Code 100 had 'OR Extending into the mediastinal fat' added; Codes 100 and 200 were clarified to indicate 'mediastinal pleura/pleura involvement' differentiates them; Code 300 is now contributing L to SS2018 rather than REEOD Mets: Note added to define when code 70 should be used; Code 30 had 'with or without lung separated pleural or pericardial nodule(s)' added; Code 50 was streamlined and Other specified distant mets was added
- Thyroid, Thyroid Medullary
EOD Mets: Bullets were added to Code 10 for Mediastinal and Distant LN NOS
- Urethra, Urethra Prostatic
EOD Primary Tumor: Note was added "In case of multifocal papillary noninvasive tumors (code 000) and nonpapillary in situ tumors (code 050), code 050."; Code 000 and 050 were revised to clarify use of 000 for 8130/2 and 8131/2 only; Code 050 had 'papillary and nonpapillary' added to clarify multifocal cancer codingSS2018: Code 0 revised to clarify Papillary and Nonpapillary, and 'Multifocal non-invasive tumors' was added
- Vagina
SS2018: Codes 1, 2 and 7 restructured; Code 3 had section for FIGO III localized tumor with regional lymph node involvement added to end
- Vulva
EOD Primary Tumor: Text from Code 150 about the invasive carcinoma being confined was moved to Code 100; Code 150 had ‘Confined to vulva, NOS’ added; Code 100, 150 and 300 had 'UNKNOWN or NO perineum involvement' added to the Vulva only sectionSS2018: All codes restructured; Code 3 had section for FIGO III and IVA localized tumor with regional lymph node involvement added to end
SSDI and Grade
NAACCR is the custodian of these fields, changes are listed here for convenience. See Change Log on https://apps.naaccr.org/ssdi/list/ for complete information.
- General
Grade Post Therapy Clin (yc) [#1068] was added to all schemasGrade Post Therapy [#3845] was renamed as Grade Post Therapy Path (yp) for clarity, and the tag was changed to Grade Post Therapy [grade_post_therapy]. This change was carried throughout all the Grade notesGrade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: New Note was added (number varies) to indicate how to handle multiple tumors with different gradesGrade Clinical [#3843]: Note regarding how to code when only one grade is available was modified for the post therapy gradesGrade Pathological [#3844]: Note 2 was added to describe what do to when clinical grade is in the preferred coding system but pathological is not, schema specific examples are provided; New Note was added (number varies) to describe how to use the grade from the clinical workup in different scenariosGrade Post Therapy Path (yp) [#3845]: Note regarding how to code when only one grade is available was modified for the post therapy grades;
- Bile Ducts Intrahepatic, Liver
Fibrosis Score [#3835]: Code 0 and code 1 had 'Any of the following histologically confirmed' added
- Bile Ducts Intrahepatic
Tumor Growth Pattern [#3935]: Code 9 had 'Radiology' added to pathology reports (does not mention…)
- Bone Appendicular Skeleton, Bone Pelvis, Bone Spine
Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: Note 5 was added to indicate Codes 1-3 take priority over Code H
- Brain, CNS Other, Intracranial Gland
Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: bullets were added to Note 4 to indicate where the list of relevant histologies can be found and how to handle Benign tumors
- Breast
Grade Clinical [#3843], Grade Pathological [#3844]: Note 7 (clin) and 8 (path) was added detailing when grade from nodal tissue may be usedER Percent Positive [#3826]: Note 5 was modified to indicate XX7 should be used; Code XX7 "Test done, results not in chart" was addedER Summary [#3827]: Code 0 was expanded to indicate percentagesHER IHC Summary [#3850], HER2 ISH Summary [#3854], HER2 Overall Summary [#3855]: Note 9 for Overall and Note 10 for IHC and ISH was added to indicate that this is not usually done for in situ cases; Code 2 for IHC and Code 9 for Overall and ISH was modified to include 'Borderline'HER2 ISH Dual Probe Ratio [#3852], HER2 ISH Dual Probe Copy Number [#3851]: Code XX.9 was modified to include Dual probe not done (only single probe)HER2 ISH Single Probe Copy Number [#3853]: Code XX.9 was modified to include Single probe not done (only dual probe)Oncotype DX Recur Score - Invasive [#3904]: 'Invasive' was added to the name to match NAACCR; Note 4 was added to specify scores from linear regression should not be captured; Note 6 was added to indicate when results from nodal or metastatic tissue may be used; Note 9 was added to clarify the same test should be used for Score and LevelOncotype DX Risk Level - Invasive [#3906]: Note 4 was added to clarify the same test should be used for Score and LevelOncotype DX Recurrence Score-DCIS [#3903], Oncotype DX Risk Level-DCIS [#3905]: Note 7 for Score and Note 5 for Level were added to clarify the same test should be used for Score and LevelPR Percent Positive [#3914]: Note 5 was modified to indicate XX7 should be used; Code XX7 "Test done, results not in chart" was addedPR Summary [#3915]: Code 0 was expanded to indicate percentagesResponse to Neoadjuvant Therapy [#3922]: Note 2 was added describing how to code in situ tumors
- Cervical Lymph Nodes, Unknown Primary of Head & Neck, Melanoma Head & Neck
Lymph Nodes Head and Neck Levels IV-V [#3877]: Note 4 was added to clarify how to handle 'supraclavicular' as the only description
- Cervix, Corpus Adenosarcoma, Corpus Carcinoma and Carcinosarcoma, Corpus Sarcoma, Fallopian Tube, Ovary, Placenta, Primary Peritoneal Carcinoma, Vagina, Vulva
FIGO Stage [#3836]: restructured from a 2 digit code to be the actual stage (1A, 2B1, etc); codes 97-99 are unaffected **(See ‘EOD v2.0 Review and Conversion’)**
- Colon and Rectum
Circumferential Resection Margin [#3823]; Note 4 was moved to Note 2; Note 3 was added to provide guidelines on how surgery codes and CRM coding relateKRAS [#3866]: Note 3 was modified and expanded to better describe the KRAS codons; Note 8 was added to define when code 9 should be used; Code 0 was expanded to include more negative termsMicrosatellite Instability (MSI) [#3890]: Note 4 had a typo fixed (dMMR rather than pMMR); Code 0 was expanded to add additional terms; code 2 was expanded to add additional termsBRAF Mutational Analysis [#3940] and NRAS Mutational Analysis [#3941] were added
- Corpus Adenosarcoma
Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: Note 5 added to indicate Code S takes priority over Codes L and H
- Corpus Carcinoma and Carcinosarcoma, Corpus Sarcoma
Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: Bullet added to Note 2 indicating specific histologies that are always grade 3
- Corpus Adenosarcoma, Corpus Sarcoma
FIGO Stage [#3836]: code 97 was removed as these can't be in situ
- Corpus Adenosarcoma, Corpus Carcinoma and Carcinosarcoma, Corpus Sarcoma
Number of Examined Para-aortic Nodes [#3899], Number of Examined Pelvic Nodes [#3900], Number of Positive Para-aortic Nodes [#3901], Number of Positive Pelvic Nodes [#3902]: Note 5 was added to clarify what to do when no lymph node dissection was performed; Code X9 was modified to include No lymph node dissection was performed
- Esophagus, Esophagus Squamous, Stomach
Schema Discriminator 1: EsophagusGEJunction/Stomach [#3926]: Note 2 was added to clarify CAP protocol vocabular differencesHER2 Overall Summary [#3855] was added
- Esophagus Squamous
Esophagus and EGJ Tumor Epicenter [#3829]: Note 6 was added to describe how to code for C159
- Head and Neck schemas (Schema ID = 00060-00150)
Extranodal Extension Head and Neck Clinical [#3831]: Note 4 had 'clinically positive' added for clarity; Note 6 added to use code 7 when Lymph nodes are clinically negative or Behavior = 2; Code 4 "Regional lymph nodes involved, ENE present/identified, unknown how identified" was addedExtranodal Extension Head and Neck Pathological [#3832]: Note 2 had a bullet was added about coding Scope of Regional Lymph Node Surgery [#1292]
- Kidney Parenchyma
Invasion Beyond Capsule [#3864], Ipsilateral Adrenal Gland Involvement [#3861], Major Vein Involvement [#3886]: Note 2 revised to indicate surgical resection must be done
- Lacrimal Gland
Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: Note 3 was added 'G4 includes anaplastic'; Codes A-D were removed as they match the standard grade definitions; Code 4 'G4: Undifferentiated' was added **(See ‘EOD v2.0 Review and Conversion’)**
- Lung
Visceral and Parietal Pleural Invasion [#3937]: Notes were revised completely; Codes 1, 2 and 4 were combined into PL1 & PL2, NOS (code 4); Code 3 was moved to Code 5 (Codes 1, 2 and 3 were removed and Codes 4 and 5 were revised) **(See ‘EOD v2.0 Review and Conversion’)**ALK Rearrangement [#3938] and EGFR Mutational Analysis [#3939] were added
- Lymphoma-CLL/SLL
Adenopathy [#3804]: bullets were added to Note 2 to clarify precedence of physician statementOrganomegaly [#3907]: Note 5 was modified to clarify when organomegaly can be coded as opposed to being unknown; Codes 0, 1 and 9 were revised to be more specific regarding this issue
- Lymphoma Ocular Adnexa
Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: Codes 5 and L are being removed; Codes 3 and 4 revised to contain all values **(See ‘EOD v2.0 Review and Conversion’)**
- Melanoma Skin
LDH (Lactate Dehydrogenase) Level [#3869], LDH (Lactate Dehydrogenase) Lab Value [#3932]: 'Pretreatment' removed from the name and 'pretx_' removed from the data item tag; this change was carried through the notes for these data items
- Merkel Cell Skin, Penis
Extranodal Extension Clinical (non-Head and Neck) [#3830]: Note 5 was added to define when to use Code 7; Code 1 was changed to WITH or WITHOUT imaging; Code 4 "Regional lymph nodes involved, ENE present/identified, unknown how identified" was addedExtranodal Extension Pathological (non-Head and Neck) [#3833]: A bullet was added to Note 4 to clarify the interaction of this field and Scope Regional Lymph Node Surgery
- NET Ampulla of Vater, NET Appendix, NET Colon and Rectum, NET Duodenum, NET Jejunum and Ileum, NET Pancreas, NET Stomach
Ki-67 was added
- Ovary, Fallopian Tube, Primary Peritoneal Carcinoma
Grade Clinical [#3843], Grade Pathological [#3844], Grade Post Therapy Path (yp) [#3845]: Note 4, first bullet was modified to specify histologies for immature teratomas and serous carcinomasResidual Tumor Volume Post Cytoreduction [#3921]: Note 4 was revised to remove neoaduvant therapy comment; Codes of 10, 20 were combined to 50; codes 30, 40 were combined to 60; codes 90, 91 were combined to 70, and codes 92-93 were combined to 80; (Codes 10-40, 90-93 were dropped, Codes 50-80 were added) **(See ‘EOD v2.0 Review and Conversion’)**
- Pancreas
CA 19-9 PreTx Lab Value was added
- Plasma Cell Myeloma
LDH (Lactate Dehydrogenase) Level [#3869], LDH (Lactate Dehydrogenase) Lab Value [#3932]: 'Pretreatment' removed from the name and 'pretx_' removed from the data item tag; this change was carried through the notes for these data items
- Prostate
Gleason Patterns Clinical [#3838]: 'TURP and/or Biopsy done' added to X6; 'Unknown whether TURP and/or Biopsy done' added to X9Gleason Patterns Pathological [#3839]: 'Prostatectomy done' added to X6; 'Unknown whether Prostatectomy done' added to X9
- Soft Tissue Abdomen and Thoracic, Soft Tissue Trunk and Extremities, Soft Tissue Other
Schema Discriminator 2 [#3927] was added to these schema for C473, C475, C493-C495. For diagnosis years 2018-2020, if the schema discriminator is 8 (Not Collected), they will be assigned to Soft Tissue Abdomen as they did in previous version **(See ‘EOD v2.0 Review and Conversion’)**C474 will continue to be assigned to Soft Tissue Abdomen and Thoracic in 2018-2020 diagnosis years; for 2021 and later years, this site will be assigned to Soft Tissue Trunk and Extremities
- Testis
AFP Post-Orchiectomy Range [#3806]: Note 6 was revised to indicate code 5 should be used; Code 5, Post-Orchiectomy AFP unknown or not done, pre-orchiectomy AFP was normal, was addedhCG Post-Orchiectomy Range [#3847]: Note 5 was revised to indicate code 5 should be used; Code 5, Post-Orchiectomy hCG unknown or not done, pre-orchiectomy hCG was normal, was addedLDH Post-Orchiectomy Range [#3847]: Note 5 was revised to indicate code 5 should be used; Code 5, Post-Orchiectomy LDH unknown or not done, pre-orchiectomy LDH was normal, was addedS Category Pathological [#3924]: Note 6 was added to describe what to do when pre-orchiectomy markers were normal and post-orchiectomy tests were not repeated; Code 5 was added to handle this scenario